You are here

New Indication for Pemetrexed In Metastatic NSCLC

Trial Demonstrated Significantly Improved Survival Rates

Pemetrexed for injection (Alimtra, Eli Lilly and Company) has received FDA approval for a new indication in combination with pembrolizumab (Keytruda, Merck) and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. 

The approval was based on data from the phase 3 KEYNOTE-189 trial, which enrolled patients regardless of PD-L1 expression and had primary endpoints of overall survival (OS) and progression-free survival (PFS).  

KEYNOTE-189 demonstrated that Alimta, in combination with pembrolizumab plus platinum-based chemotherapy, resulted in significantly longer OS and PFS than ALIMTA plus platinum chemotherapy with placebo. 

Severe adverse reactions occurring in ≥20% of patients included fatigue, diarrhea, dyspnea, vomiting, nausea, rash, decreased appetite, constipation, and pyrexia.

Source: Eli Lilly and Company, January 31, 2019

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time